Fol­low­ing top-lev­el C-suite de­par­tures, As­cle­tis raids No­var­tis for R&D ex­ec

As­cle­tis has wooed an­oth­er top phar­ma ex­ec from the US to Chi­na as it gets ready to show that its R&D team has what it takes to come up with some first-in-class drugs.

In tak­ing up the CSO role Han­dan He is leav­ing be­hind a 22-year stint at No­var­tis, where her last ti­tle was glob­al head of com­pu­ta­tion­al, bio­phar­ma­ceu­tics and trans­la­tion­al PK/PD.

Her ar­rival marks an­oth­er big get for CEO Jinzi Wu, who ear­li­er this year re­cruit­ed Mer­ck’s top drug de­vel­op­er in Chi­na as As­cle­tis’ CMO. But health and fam­i­ly con­cerns cut Zhengqing Li’s tenure short, forc­ing him to de­part af­ter on­ly five months. Days ago CFO Lin­di Tan al­so hand­ed in her pa­pers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER